BRPI0415051A - compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas - Google Patents

compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas

Info

Publication number
BRPI0415051A
BRPI0415051A BRPI0415051-1A BRPI0415051A BRPI0415051A BR PI0415051 A BRPI0415051 A BR PI0415051A BR PI0415051 A BRPI0415051 A BR PI0415051A BR PI0415051 A BRPI0415051 A BR PI0415051A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compounds
melanin
concentrating hormone
antagonist compounds
Prior art date
Application number
BRPI0415051-1A
Other languages
English (en)
Inventor
Xiufeng Eric Hu
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BRPI0415051A publication Critical patent/BRPI0415051A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTOS ANTAGONISTAS DO HORMÈNIO CONCENTRADOR DE MELANINA E SUAS COMPOSIçõES FARMACêUTICAS". A presente invenção refere-se a compostos capazes de servir como moderadores do apetite em seres humanos e mamíferos e, como tal, proporcionar um meio para a redução da massa corpórea. Os compostos da presente invenção são seletivos contra o hormónio concentrador de melanina, e não apresentam os efeitos colaterais perniciosos resultando de compostos que interagem com outros receptores cerebrais relacionados ao apetite.
BRPI0415051-1A 2003-10-01 2004-09-24 compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas BRPI0415051A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50777303P 2003-10-01 2003-10-01
US53664004P 2004-01-15 2004-01-15
PCT/US2004/031631 WO2005033063A2 (en) 2003-10-01 2004-09-24 Melanin concentrating hormone antagonists

Publications (1)

Publication Number Publication Date
BRPI0415051A true BRPI0415051A (pt) 2006-11-28

Family

ID=34426018

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415051-1A BRPI0415051A (pt) 2003-10-01 2004-09-24 compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas

Country Status (20)

Country Link
US (1) US7304065B2 (pt)
EP (1) EP1667958A2 (pt)
JP (1) JP2007508303A (pt)
KR (1) KR20060060047A (pt)
CN (1) CN101068773A (pt)
AR (1) AR045958A1 (pt)
AU (1) AU2004278352B2 (pt)
BR (1) BRPI0415051A (pt)
CA (1) CA2540826A1 (pt)
CO (1) CO5690589A2 (pt)
IL (1) IL174370A0 (pt)
IS (1) IS8360A (pt)
MA (1) MA28079A1 (pt)
MX (1) MXPA06003654A (pt)
NO (1) NO20061953L (pt)
PE (1) PE20050475A1 (pt)
RU (1) RU2006110272A (pt)
SG (1) SG146692A1 (pt)
TW (1) TW200526554A (pt)
WO (1) WO2005033063A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001160A1 (en) * 2006-06-23 2008-01-03 The Procter & Gamble Company Melanin concentrating hormone antagonists
MX2009000110A (es) * 2006-06-28 2009-01-23 Glaxo Group Ltd Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor grp38.
US20100081825A1 (en) * 2006-10-06 2010-04-01 Taisho Pharmaceutical Co Ltd 1-naphthyl alkylpiperidine derivative
JP2010525069A (ja) * 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
EP2025674A1 (de) * 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW201010997A (en) * 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
UY32443A (es) * 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
EP2522657B1 (en) * 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Indole derivative

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206428A (en) * 1989-11-16 1993-04-27 Tanabe Seiyaku Co., Ltd. Tetrahydronaphthalene derivatives and preparation thereof
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JPH08506817A (ja) * 1993-02-12 1996-07-23 メルク エンド カンパニー インコーポレーテッド スピロ（２ｈ−１−ベンゾピラン−２，４′−ピペリジン）クラス▲ｉｉｉ▼抗不整脈薬
WO1994027597A1 (en) * 1993-05-21 1994-12-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acid angiotensin ii receptor antagonists
AU2565595A (en) 1994-05-28 1995-12-21 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
DE4438029A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K N.N-disubstituierte Benzocycloalkylamine, ihre Salze mit verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
AU5147196A (en) * 1995-03-27 1996-10-16 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic a gents
DE19614718A1 (de) * 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
ES2300119T3 (es) 1997-02-27 2008-06-01 Takeda Pharmaceutical Company Limited Compuestos de amina, su produccion y su uso como inhibidores de la produccion de beta-amiloide.
US6747023B1 (en) * 1998-08-11 2004-06-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
JP4025200B2 (ja) 2000-12-22 2007-12-19 シェーリング コーポレイション ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
EP1432693A2 (en) 2001-10-01 2004-06-30 Taisho Pharmaceutical Co. Ltd. Mch receptor antagonists
CN100548291C (zh) 2001-10-25 2009-10-14 先灵公司 用于治疗肥胖的mch拮抗剂
KR20040058307A (ko) 2001-11-26 2004-07-03 쉐링 코포레이션 비만 및 ｃｎｓ 장애를 치료하기 위한 피페리딘계 ｍｃｈ길항제
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
IL162311A0 (en) 2001-12-04 2005-11-20 Schering Corp N-aryl-n'-arylcycloalkyl-urea derivatives aas mch antagonists for the treatment of obesity
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2503405A1 (en) * 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Treating syndrome x with substituted tetralins and indanes
US7425631B2 (en) * 2003-04-10 2008-09-16 Amgen Inc. Compounds and methods of use

Also Published As

Publication number Publication date
IL174370A0 (en) 2006-08-01
CA2540826A1 (en) 2005-04-14
AU2004278352A1 (en) 2005-04-14
AU2004278352B2 (en) 2008-10-30
AR045958A1 (es) 2005-11-16
NO20061953L (no) 2006-06-13
EP1667958A2 (en) 2006-06-14
WO2005033063A3 (en) 2007-03-22
US20050075324A1 (en) 2005-04-07
IS8360A (is) 2006-03-17
TW200526554A (en) 2005-08-16
JP2007508303A (ja) 2007-04-05
US7304065B2 (en) 2007-12-04
CO5690589A2 (es) 2006-10-31
KR20060060047A (ko) 2006-06-02
RU2006110272A (ru) 2007-11-10
WO2005033063A2 (en) 2005-04-14
MA28079A1 (fr) 2006-08-01
PE20050475A1 (es) 2005-10-05
CN101068773A (zh) 2007-11-07
SG146692A1 (en) 2008-10-30
MXPA06003654A (es) 2006-06-05

Similar Documents

Publication Publication Date Title
UY26130A1 (es) Compuestos para tratar la obesidad
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
EP2592072A3 (en) Human protein tyrosine phosphatase inhibitors and their use
BRPI0515316A (pt) compostos de imidazoquinolina
BRPI0405166A (pt) Composição de cuidados pessoais e processo para preparar a mesma
GT199900203A (es) Composiciones de celecoxib.
EP2592073A3 (en) Human protein tyrosine phosphatase inhibitors and their use
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
BRPI0417072A (pt) agente preventivo para a vasculite
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0615307A2 (pt) agonistas de adrenorreceptor alfa2c
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0708965B8 (pt) composição farmacêutica de metilnaltrexona
BRPI0418166A (pt) compostos de bicicloeteroarilamina como ligandos de canal de ìon e usos destes
CL2007003640A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento en que la afeccion es dolor, tales como dolor lumbar y cervical, migrana, dismenorrea, dolor de muelas, entre otros.
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
CL2003002043A1 (es) Compuestos derivados de tetrahidropiridina sustituidos en posicion 3 y 4; composicion farmaceutica, y sus usos en el tratamiento de enfermedades que estan asociadas con el sistema renina-angiotensina (ras), tales como hipertension, insuficiencia card
BRPI0415051A (pt) compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
WO2010019611A3 (en) Bridged polycyclic compound based compositions for topical and oral applications
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
CL2007001802A1 (es) Compuestos derivados de fenil metanona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso en trastornos neurologicos y neuropsiquiatricos, tales como sicosis, dolor, esquizofrenia, demencias y otras enfe

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.